The potential of gallic acid as a radiosensitizer on human prostate cancer: A systematic review of preclinical studies

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)

Abstract

Prostate adenocarcinoma accounts for majority of prostate cancer cases, and it was found to be highly radioresistant. Gallic acid is a phenolic acid naturally occurring in many plants, reported to exhibit biological activities in eliminating cancer cell lines and xenografts. The purpose of this study is to review gallic acid as a potential radiosensitizer agent in prostate cancer treatment. Article search was conducted in PubMed, EBSCO, and Scopus. 11 studies using different cell lines including DU145, PC-3, LNCaP, and 22Rv1 xenograft of human prostate cancer were reviewed in this paper. Gallic acid acts as a radiosensitizer mainly by increasing caspase-3 and caspase-9 activation resulting in apoptosis, while also reducing intracellular CDKs, cyclins, and cdc25 phosphatases ultimately causing G2-M cell cycle arrest. Gallic acid has a potential to be a new radiosensitizer compound in prostate cancer treatment. Additional clinical studies using gallic acid derivatives with lower hydrophilicity are needed.

Original languageEnglish
Pages (from-to)246-254
Number of pages9
JournalMalaysian Journal of Medicine and Health Sciences
Volume17
Issue number2
Publication statusPublished - Apr 2021

Keywords

  • Apoptosis
  • Gallic acid
  • Prostate cancer
  • Radiobiology
  • Radiotherapy

Fingerprint

Dive into the research topics of 'The potential of gallic acid as a radiosensitizer on human prostate cancer: A systematic review of preclinical studies'. Together they form a unique fingerprint.

Cite this